Highest-materiality recent filing
Nordson Q2 record sales $741M (+8% YoY) and adj EPS $2.86 (+18% YoY); raises FY outlook
Net income $117M, $2.09 diluted EPS; adjusted diluted EPS $2.86 (record, +18% YoY).
Nordson Q1 record sales $669M (+9% YoY); raises FY adj. EPS guidance to $11.00-$11.60
Q1 GAAP EPS $2.38 (up 44% YoY); adjusted EPS $2.37 (record, up 15%).
Nordson enters $1.2B revolving credit facility, repays $248M term loans
New $1.2B senior unsecured multicurrency revolving credit facility matures January 30, 2031.
Nordson reports record FY2025 sales of $2.8B; adj. EPS $10.24, up 5% YoY
Q4 sales $752M (+1% YoY); diluted EPS $2.69; adj. diluted EPS $3.03 (+9% YoY).
Nordson Q3 sales $742M (+12%), adjusted EPS $2.73 (+13%); board adds $500M buyback
Q3 sales $742M, up 12% YoY; organic sales up 2%; acquisition impact 8%.
Nordson separation agreement for departing segment leader Lovass: $832,759 cash, continued vesting
Stephen Lovass ceased as Medical and Fluid Solutions segment leader; assists transition until June 1, 2025, then separates.
Nordson Q2 FY2025 sales $683M (+5%), adj EPS $2.42 beats midpoint; Q3 guide $710-750M
Q2 sales $683M (+5% YoY) with 8% acquisition benefit offset by 2% organic decline.
the Original Form 8-K reported that, on April 28, 2025, Stephen Lovass ceased to serve as segment leader for the Medical and Fluid Solutions Segment of Nordson Corporation
Max materiality 0.85 · Median 0.68 · Most common event earnings